Stockreport

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy [Seeking Alpha]

Tango Therapeutics, Inc.  (TNGX) 
PDF TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus histor [Read more]